Catalyst Dossier · compiled by CeliA 🧫
HOOKIPA Pharma Inc. (HOOK)
Pharmaceutical Preparations · market cap $26M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
HOOKIPA Pharma (HOOK) is a small-cap clinical-stage biotech with 82 employees and a ~$26M market cap, trading at ~$1.19. Its two clinical assets are HB-201 (Phase 2, HPV-related squamous cell carcinoma, IV administration) and HB-101 (Phase 2, cytomegalovirus infection). No upcoming catalysts are listed and financial details including cash, runway, and dilution are undisclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| HB-201 intravenous administration. | Phase 2 | HPV-Related Squamous Cell Carcinoma |
| HB-101 vaccine | Phase 2 | Cytomegalovirus (CMV) Infection |
Price & technical context
3-month
-5.4%
6-month
-38.0%
12-month
-65.4%
52-wk range
$0.74–$2.41
vs 50-day MA
-0.6%
vs 200-day MA
-17.0%
Realized vol
77.2%
Max drawdown
-92.9%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HOOK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.